Tian Zhang, MD, MHS

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Acerta, Novartis, Merrimack, Abbvie/StemCentrx, Merck, Regeron, Mirati Therapeutics, Janssen, AstraZeneca, Pfizer, OmniSeq, Personal Genome Diagnostics, Astellas
    Topic:
    PI (research funding)
    Date added:
    03/22/2022
    Date updated:
    04/11/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Pfizer, MJH Associates, Vaniam, Aptitude Health, PeerView, Clinical Care Options
    Topic:
    Consultant
    Date added:
    03/22/2022
    Date updated:
    04/11/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Merck, Exelixis, Sanofi-Aventis, Janssen, AstraZeneca, Pfizer, Amgen, BMS, Pharmacyclics, SeaGen, Calithera, Dendreon, QED Therapeutics, Eisai, Aveo Pharmaceuticals, Bayer, Eli Lilly
    Topic:
    Advisory Board
    Date added:
    03/22/2022
    Date updated:
    04/11/2024
Return to 109 Division OF Hem/Onc: Oncology Board Review Conference " " (120822)